bluuebunny/crossref_metadata_2025_split huggingface dataset:
Malignant lymphoma in Hawaii‐Japanese: A retrospective morphologic survey
Authors: Yanagihara Eugene T. , Blaisdell Richard K. , Hayashi Takuji , Lukes Robert J. 
Published: February 2007

AbstractA retrospective morphologic survey (1973–1983) of 146 cases of malignant lymphoma among the Hawaii‐Japanese (migrant Japanese and their offspring) was conducted to determine whether differences in the incidence and cytologic types of malignant lymphoma exist when compared to those of native Japanese (lifetime residents of Japan). The age‐adjusted incidence rates for malignant lymphoma among the Hawaii‐Japanese were similar to rates for U.S. whites. However, higher rates for follicular centre cell (FCC) lymphoma with a follicular pattern were observed in the Hawaii‐Japanese population when compared with rates for native Japanese.On the basis of the cytologic types of the Lukes–Collins classification, non‐Hodgkin's lymphomas among the Hawaii‐Japanese resembled those of Western countries, rather than those of Japan. B‐cell lymphomas predominated (72 per cent), while T‐cell types comprised 23 per cent of cases. Follicular centre cell types were encountered most often (59 per cent), and the small cleaved FCC subtype was the most common (30 per cent). The high degree of follicularity (29 per cent) was at variance with the consistently low rates reported in Japan. This may be explained, in part, by higher rates of nodal lymphomas among the Hawaii‐Japanese. Of the T‐cell lymphomas, diffuse large cell types (T‐cell immunoblastic sarcoma, T‐IBS), often with cytologic pleomorphism, were relatively frequently encountered (16 per cent), and comprised 15 per cent of non‐Hodgkin's lymphomas; this observation necessitates special clinical and epidemiologic consideration in view of the large Japanese migration to Hawaii from HTLV‐I endemic regions of southern Japan. No registered cases of non‐Hodgkin's lymphoma or of Hodgkin's disease were documented in Hawaii‐Japanese subjects under the age of 15 years.The age‐adjusted incidence rates for Hodgkin's disease among the Hawaii‐Japanese were similar with those of native Japanese. Nodular sclerosis was the most frequent histologic subtype. The difficulty in distinguishing between Hodgkin's disease and non‐Hodgkin's lymphoma, particularly when immunologic cell surface markers are not available, is addressed.Low rates for chronic lymphocytic leukemia among the Hawaii‐Japanese were confirmed. Not one well‐documented case was identified in the 11‐year period surveyed.
A monoclonal antibody 1A6 to T‐cell recognizes a common antigen expressed on lymphocytes from normal and leukemic patients, and inhibits nk cell activity
Authors: Togashi Hiroyuki , Ghoneum Mamdooh , Takasugi Mitsuo , Kasai Kiyoshi , Mugishima Hideo , Billing Ronald , Terasaki Paul. I. 
Published: February 2007

AbstractA new monoclonal antibody (MAB), IA61gG2a, has been derived from Balb/c mice after immunization with T‐cell chronic lymphocytic leukemia (T‐CLL). This monoclonal antibody, 1A6 was tested on normal human peripheral blood cells, leukemia patient's cells and leukemia‐lymphoma cell lines. The results demonstrated that this antibody reacts with normal human T and B cells, but not with erythrocytes, granulocytes or platelets. Further examinations showed 10/11 leukemic patient cell types were positive with 1A6. In contrast, many leukemia‐lymphoma cell lines were negative (14/17), i.e. T and B leukemia lymphoma cell lines, non‐T and non‐B leukemia cell lines as examined by complement mediated cytotoxicity test and immunofluorescence test. Other prominent characteristics of 1A6 MAB have been demonstrated, which include inhibition of myeloid colony formation (CFU‐C) and suppression of human natural killer cell cytotoxicity (NKCC). These results suggest that 1A6 is a common marker for normal T, B, NK cells and leukemic patients cells having T and B cell origin, but 1A6 antigen is not expressed on many leukemia lymphoma cell lines. Therefore, it could be useful for studying malignant transformation of lymphoid cells.
Treatment of refractory acute myeloid leukemia with mAMSA and VP 16‐213 in combination: Results of a clinical phase I/II study
Authors: Hiddemann Wolfgang , Urbanitz Dieter , Preusser Peter , Achterrath Wolf , Büchner Thomas 
Published: February 2007

AbstractTwenty patients with refractory AML were treated with mAMSA and VP 16–213 in combination to assess the toxicity and anti‐leukemic activity of the two‐drug regimen. Refractoriness was defined according to the response to induction therapy consisting of 6‐thioguanine, cytosine arabinoside and daunorubicin (TAD9) and the duration of the preceding remission. Patients were eligible for AMSA/VP 16–213 if they were primary non‐responders against two TAD9 induction courses, had early relapses within the first six months, were non‐responders to one additional TAD9 course at later relapses or were at second or subsequent relapses. Therapy consisted of a five‐day course of mAMSA 210 mg/m2/d on days 2, 3 and 4. VP 16–213 was applied on days 1 and 5 by a 1‐h infusion of 100 mg/m2 followed by a 23 h infusion, the dosage of which was escalated in three steps from 110 mg/m2 over 200 mg/m2 to 230 mg/m2 in subsequent patients.Even at the highest dose of VP 16–213, toxicity was mild to moderate except for mucositis of grade III after two cycles and severe intrahepatic cholestasis in one case. Four of the 20 patients died within the first three weeks after the onset of treatment and were not evaluable for the assessment of antileukemic efficacy. From the remaining 16 patients five achieved partial remissions while no complete remission was obtained. Four of the five PR occurred in the eight patients with primary TAD9 resistance.These data indicate that AMSA/VP 16–213 reveals a moderate toxicity only, and that the combination may not be completely cross‐resistant with TAD9. The overall anti‐leukemic activity is limited however, and seems inferior compared to other presently available salvage regimens in refractory AML.
Absent clinical effects of retinoic acid and isoretinoin treatment in the myelodysplastic syndrome
Authors: Hast Robert , Laurén Sten Axdorph Lillemor , Reizenstein Peter 
Published: February 2007

AbstractTen patients with the myelodysplastic syndrome (eight with anemia, two with granulocytopenia, four with thrombocytopenia) were given etretinate (ER) and retinoid acid (RA). No correlation was seen between the RA effect in vitro and its clinical effect. No effect was seen of the ER‐treatment or of the RA‐treatment on anemia, thrombocytopenia or the abnormal karyotype seen in three patients. In three of eight patients given RA a decreased blast cell percentage in the bone marrow was seen, and in two of these there was also a normalization of the in vitro bone marrow cell colony formation. We found no clinical effect of ER and only a minimal one of RA.
Cytogenetics and their prognostic value in childhood and adult acute lymphoblastic leukemia (ALL) excluding L3
Authors: Fenaux P. , Lai J. L. , Morel P. , Nelken B. , Taboureau O. , Deminatti M. , Bauters F. 
Published: February 2007

AbstractCytogenetic analysis was made at diagnosis in 174 cases of ALL (101 children less than 20 years and 73 adults), excluding Burkitt's ALL (L3). In 11 children (11 per cent) insufficient material was obtained. In the remaining 90, 50 (56 per cent) had a normal karyotype, 20 (22 per cent) a hyperdiploid karyotype, five (6 per cent) a hypodiploid karyotype, 12 (13 per cent) had a translocation (including seven cases of t(1;19)) and three had a pseudodiploid karyotype without translocation. Ninety‐eight per cent of patients reached complete remission (CR). Median actuarial CR duration was not attained, was 50 months, 13 months and 11 months respectively in patients with hyperdiploid, normal, hypodiploid karyotype and in patients with a translocation, the difference between subgroups being significant. In a Cox model, cytogenetics were the strongest factor predicting CR duration (p= 0.03) followed by leukocytes (p= 0.04), whereas the presence of ‘bulky disease’ had a borderline value (p= 0.077). Of note was that 9/17 (53 per cent) patients with a hypodiploid karyotype or a translocation had no ‘risk factors’ before cytogenetic analysis.In adults, cytogenetic analysis was unsuccessful in 15 (20 per cent) of patients. In the remaining 58 cases, 19 (33 per cent) had a normal karyotype, 15 (26 per cent) had a hyperdiploid, one (2 per cent) had a hypodiploid karyotype, 19 (33 per cent) had a translocation (including 12 t(9;22)), and four (7 per cent) had a pseudodiploid without translocation. 73 per cent patients reached CR. Median actuarial DFS was 12.5 months. No significant differences in CR rate and CR duration were seen between cytogenetic groups, but median CR duration was slightly longer in patients with a normal karyotype (17 months) and shorter in patients with t(9; 22) (8.5 months). Only 3/12 of the latter had major risk factors before cytogenetic analysis. Cytogenetic analysis is important in ALL, especially in patients with otherwise standard risk factors, as it may reveal unexpected translocations or hypodiploidy, which may require a therapeutic reinforcement.
Malignant lymphomas of follicular centre cell origin in man. VII. Prognostic features in small cleaved cell lymphoma
Authors: Stein Richard S. , Greer John P. , Cousar John B. , Hendey Gregory W. , Wehner John H. , Flexner John M. , Collins Robert D. 
Published: February 2007

AbstractTo extend the clinical‐pathologic description of small cleaved cell lymphoma (SCCL), we reviewed the records of 106 patients with SCCL who were treated in accordance with a policy of watchful waiting and palliative therapy. Median age was 58 years. A pure diffuse pattern was seen in only 16 per cent of cases. Stage III or IV disease was present in 85 per cent of patients; marrow involvement was noted in 60 per cent of patients. ‘B’ symptoms were present in 25 per cent of patients.By univariate analysis, age > 60, diffuse pattern, stage IV disease, involvement of liver, lung, pleura, or g‐1 tract, ‘B’ symptoms, surface heavy chain IgM or IgM‐D, and LDH > 200 IU/dl were found to be significantly associated with a poor prognosis. Marrow involvement, increased (5–25 per cent) transformed (non‐cleaved) cells, and surface light chain had no prognostic significance.By multivariate analysis, only age >60, stage IV disease, and LDH > 200 IU/dl were prognostically significant. For patients with all three unfavourable prognostic features, median survival was only 11 months. For patients with age ± 60, stage I, II, or III disease, and LDH ± 200 IU/dl, median survival was not reached at 180 months. Recognition of prognostic features in indolent lymphoma can help clarify whether the results of treatment protocols represent true advances or the mere selection of favourable patients.
Refractory acute lymphocytic leukemia: Response to aclacinomycin a and VP‐16‐213
Authors: Rowe Jacob M. , Chang Alex Y. C. , Bennett John M. 
Published: February 2007

AbstractTwelve patients with acute lymphoblastic leukemia (ALL) were treated with aclacinomycin A (60 mg/m2/day for five days) and VP‐16‐213 (100 mg/m2/day). All were heavily pretreated and had relapsed or were refractory to primary or subsequent treatment. Eight patients were refractory to reinduction therapy given for first, second, third or fourth relapse. One patient was treated in third relapse; one in second relapse (after a short second remission) and two in first relapse—one with the Ph1 chromosome, after a four‐month remission, and one patient who relapsed while receiving consolidation therapy. Four patients (33 per cent) responded, three entered complete remission (25 per cent), and one a partial remission (8 per cent). Two of the patients treated for refractoriness to reinduction therapy went into complete remission. Side effects from this treatment were similar to the conventional DAT regimen (daunorubicin, cytosine arabinoside, thioguanine), although the gastrointestinal toxicity and mucositis appeared to be more severe in this study population. One of the patients had severe ventricular arrhythmias which contributed to her death. The complete remission rate (25 per cent) in this group of very heavily pretreated ALL patients warrants further studies to evaluate these preliminary findings.
Prognostic implications of cell kinetics, histopathology and pathologic stage in non‐Hodgkin's lymphomas
Authors: Silvestrini R. , Costa A. , Giardini R. , Boracchi P. , Del Bino G. , Marubini E. , Rilke F. 
Published: February 2007

AbstractCell kinetics ([3H]‐thymidine labelling index, [3H]‐Thy LI) were determined on pathologic lymph nodes from 175 untreated adult patients. [3H]‐Thy LI significantly differed in low‐grade and high‐grade malignancy groups according to the Kiel classification (median values, 1.8 per cent and 10.4 per cent, respectively) and in low, intermediate, high grade according to the Working Formulation (median values: 1.7 per cent, 4.8 per cent and 14.2 per cent, respectively) but was unrelated to pathologic stage or patient's age. Cell kinetics, histo‐pathology, pathologic stage and patient's age were significant discriminants of 6‐year survival. Multivariate analysis was performed by Cox's proportional hazard model to investigate the role of [3H]‐Thy LI after making allowance for the other prognostic factors. When [3H]‐Thy LI was added to the model, a large increase (chi square = 29.94) contributed by the cell kinetic variable in identifying patients at different risk was revealed.
Oral idarubicin in the treatment of acute myelogenous leukaemia and the blast phase of chronic myeloid leukaemia
Authors: Malik S. T. A. , Tucker J. , Rohatiner A. Z. S. , Brace W. , Lister T. A. 
Published: February 2007

AbstractFourteen patients with poor‐risk acute myelogenous leukaemia (AML) and five patients with accelerated phase/blast crisis chronic myeloid leukaemia (CML) were treated with 3 days of oral idarubicin (25 mg/m2/day). No complete remissions or return to chronic phase CML were observed. A fall in the peripheral blast count was seen in all patients with the first cycle of treatment, and with subsequent cycles in CML patients, but all responses were transient, with eventual reemergence of peripheral blasts. In some patients, there was a clear cut improvement in symptoms such as bone and splenic pain. Five of the AML patients and all of the CML patients were treated as out‐patients. In this group of patients oral idarubicin was found to be a useful drug for palliative treatment.
Phase 2 study of mitozantrone in combination with chlorambucil and prednisolone for relapsed and refractory non‐Hodgkins lymphoma
Authors: Jones L. , Cotter F. E. , Lord D. , Newland A. C. 
Published: February 2007

AbstractThirty‐six patients with non‐Hodgkin's lymphoma (NHL) (comprising patients with refractory or relapsed disease and eight elderly, unfit patients with de novo disease) were treated with mitozantrone, chlorambucil and prednisolone on an out‐patient basis. Fifteen patients had low grade (LG) disease, five patients intermediate grade (IG) disease and 16 patients high grade (HG) disease and 31/36 had stage IV disease. All elderly patients had IG or HG disease. The regimen was well‐tolerated. After six courses of chemotherapy, there was a 69 per cent response rate with 33 per cent in complete remission. The median duration of remission was 15 months. The overall 3‐year projected survival was 38 per cent; 27 per cent for LG disease and 47 per cent for HG and IG disease. Responses did not appear durable for either HG or LG disease unless CR was achieved early on. Three of the eight patients treated de novo (mean age 71 years) have survived, disease‐free, between 28 and 38 months from entry. This study indicates that mitozantrone‐based regimens have promising activity in NHL and require further evaluation. The low toxicity combined with worthwhile remissions make this an attractive first‐line option for elderly patients.
Immunophenotype of blast cells in acute myeloid leukemia may be a useful predictive factor for outcome
Authors: Tucker J. , Dorey E. , Gregory W. M. , Simpson A. P. F. , Amess J. A. L. , Lister T. A. , Horton M. A. 
Published: February 2007

AbstractThe immunophenotype of peripheral blood blast cells was tested in 92 patients with acute myeloid leukemia (AML), who were diagnosed and treated at single centre, St Bartholomew's Hospital, from 1978‐1987 with a standard adriamycin, cytosine arabinoside and 6‐thioguanine regimen. Immunological analysis involved standard fluorescence flow cytometry and utilized 31 monoclonal antibodies to known myeloid antigens (of CD groups 11b, 11c, 13, 14, 15, 16, w17, 31, w32, 33, 34, 35 and 36), a number of relatively less well studied antibodies with potential specificity for AML, and a series of control antibodies to T and B lymphocytes, platelets, erythrocytes and of widespread distribution (CD45, leucocyte common; HLA‐DR). The results highlighted a number of antibodies with wide myeloid reactivity, in addition to CD13 and 33 (present in 66 per cent and 76 per cent of cases, respectively), which may be of immunodiagnostic use. A number of correlations between AML cell immunophenotype and FAB morphology subtype were found; in particular five antibodies (CD11c, 10.1, Tu3, CD15 and CD16), of both predominant granulocytic and monocytic reactivity, reacted with cells of AML‐M5 subtype (p<0.05). There was no significant correlation between immunophenotype and clinical and pathological features at presentation. Correlation with clinical outcome was not a prominent feature, in contrast to some reports based on multicentre data. However, of particular note was the strong association between early death (at less than 2 months) and the coexpression of Leucocyte Function Associated (LFA) antigens, CD11b and 11c, on patient's blast cells (p=0.003). The relationship was independent of clinical features and persisted even if AML‐M5 cases were excluded. The significance of this latter finding is unclear, but may be related to the known role of CD11b and 11c LFA antigens in the cellular response to infection.
The myelotoxicity of carboplatin is influenced by the time of its administration
Authors: Kerr D. J. , Lewis C. , O'Neil B. , Lawson N. , Blackie R. G. , Newell D. R. , Boxall F. , Cox J. , Rankin E. M. , Kaye S. B. 
Published: February 2007

AbstractPrevious studies have demonstrated that there are circadian rhythms in susceptibility to a range of commonly used cytotoxic drugs. In this study we have compared the pharmacokinetics and myelotoxicity of carboplatin administered at 18.00 and 06.00 in random order in patients with advanced ovarian carcinoma. Carboplatin treatment at 06.00 is associated with significantly greater thrombocytopenia than at 18.00 (platelet nadir 95 000 versus 180 000, p < 0.05). There was no pharmacokinetic difference in the patients' handling of ultra‐filterable platinum therefore it is possible that there is an intrinsic rhythm of susceptiblity of bone marrow to carboplatin.
The relation between hypocholesterolemia and degree of maturation in acute myeloid leukemia
Authors: Zyada L. E. , Hassan H. T. , Rees J. K. H. , Ragab M. H. 
Published: February 2007

AbstractPlasma cholesterol concentrations were determined in 83 acute myeloid leukemia patients. Mean plasma cholesterol concentration (± S.D.) at the time of diagnosis was 2·91 mmol/L(± 1·13). The percentage of AML patients having hypocholesterolemia was 90·4 per cent. The lowest cholesterol levels were observed in the poorly differentiated FAB subtypes of acute myeloid leukaemia: AMyL(M1) and AMoL(M5a). The results showed that the initial hypocholesterolemia in acute myeloid leukemia is significantly related to the degree of both cytological and cytochemical maturation of leukemic blast cells at diagnosis. The degree of maturation at diagnosis has been shown to be related to prognosis in favour of more differentiated subtypes of acute myeloid leukemia. Also, hypocholesterolemia has been shown in several epidemiological studies to be related to an increased mortality from human cancer. Therefore, the degree of maturation may serve as a link between hypocholesterolemia and the increased mortality from human cancer.
Conversion of high grade lymphoma tumor cell line to intermediate grade with tpa and bryostatin 1 as determined by polypeptide analysis on 2D gel electrophoresis
Authors: Al‐Katib Ayad , Mohammad Ramzi M. , Mohamed Anwar N. , Pettit George R. , Sensenbrenner Lyle L. 
Published: February 2007

AbstractA high‐resolution two‐dimensional polyacrylamide gel electrophoresis (2D‐PAGE) was used for total cellular polypeptide mapping of two established lymphoma cell lines; MANCA, a Burkitt's line representing a high grade lymphoma (HGL) and WSU‐NHL (nodular histiocytic lymphoma) representing an intermediate grade lymphoma (IGL). Gels were digitized and analysed with an image scanning computer using the Elsie 4 system. Polypeptide mapping revealed striking similarities in 1100 polypeptide spots in both types. However, three polypeptides were unique to HGL (Molecular mass/isoelectric point (Mr/PI): 39/4·4, 35/5·6, 33/4·8), and one to IGL (95/4·7). In order to investigate the kinetics of expression of these polypeptides, the two cell lines were treated with two protein kinase C (PKC) activators, tumour promoting 12‐O tetradecanoylphorbol 13‐acetate (TPA) and bryostatin 1. 2D‐PAGE of the treated cells revealed that the HGL line loses its unique polypeptides and expresses a new one. The new polypeptide has the same Mr and PI as that unique to the untreated IGL (95/4·7). TPA or bryostatin 1 treatment of the IGL line for 72 h induced no significant changes. Our data show a unidirectional change from HGL to IGL, supporting the clinical notion that HGL is less differentiated than IGL. It also shows the similarity in the mode of action of bryostatin 1 and TPA in inducing these polypeptide changes.
Inducible lymphokine‐activated killer (LAK) cell activity in the peripheral blood of patients with relapsed/refractory non‐Hodgkin's lymphoma (NHL)
Authors: Zamkoff Kenneth W. , Watman Nora P. , Duggan David B. , Poiesz Bernard J. , Gottlieb Arlan J. 
Published: February 2007

AbstractTherapy with recombinant interleukin‐2 (rIL‐2) induces clinical response in a significant number of patients with refractory malignant disease. Very few patients with non‐Hodgkin's lymphoma (NHL) have been treated with rIL‐2. The present study sought to determine if peripheral blood mononuclear cells (PBM) from patients with relapsed/refractory non‐Hodgkin's lymphoma could be induced in vitro to generate LAK cell activity. PBM from 28 patients with relapsed/refractory NHL were incubated for 7 days in rIL‐2 to determine their ability to lyse the LAK cell sensitive Daudi cell line. The PBM from all patients were able to generate LAK activity after in vitro incubation in rIL‐2. Approximately one third of the patients' PBM samples generated less activity than activity generated in the PBM sample from normal control donors. However, two‐thirds of patient samples were able to generate activity equal to or greater than that of the controls. The degree of LAK activity generated by the patients' PBM did not correlate either with histologic subtype or amount of prior chemotherapy. The amount of LAK activity an individual generated (control or patient) tended to remain stable over time.